Evolent Health stock gains 8.04 percent on the NYSE

Published on 10/20/2026 at 19:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sixteen analysts set a USD 5.96 average target on October 7, 2026. Evolent Health stock costs EUR 4.31 on October 20, 2026 after hours.

Price and reporting facts

Evolent Health stock gained 8.04 percent on the NYSE on October 20, 2026.
Evolent Health reported second-quarter 2026 revenue of USD 652.52 million, up 46.90 percent year over year.
Evolent Health stock costs EUR 4.31 at Lang & Schwarz on October 20, 2026 at 7:01 p.m. CEST.
Evolent Health will release third-quarter 2026 results on November 5, 2026.

EVH, US30050B1017, Illustration mit AI erstellt.

Evolent Health (ISIN US30050B1017) was trading at EUR 4.31 at Lang & Schwarz on October 20, 2026 at 7:01 p.m. CEST. On the NYSE, the stock stood at USD 4.84 on October 20, 2026 at 1:05 p.m. ET, up 8.04 percent from USD 4.48. The company is also approaching its next quarterly report, scheduled for November 5, 2026.

Revenue reached USD 652.52 million

Evolent reported revenue of USD 652.52 million for the second quarter of 2026, up 46.90 percent from the same quarter a year earlier, according to Yahoo Finance on October 5, 2026. The report also said Evolent exceeded analysts' revenue expectations by 9.40 percent and surpassed earnings-per-share expectations, while full-year revenue guidance was above consensus.

The standardized second-quarter figures show a different pressure point beneath that growth. Operating profit was negative USD 9.56 million, net income attributable to common shareholders was negative USD 28.36 million and diluted earnings per share were negative USD 0.25 for the quarter. Operating cash flow was negative USD 9.31 million in the same period.

Stock remains below its yearly high

The NYSE quote reached USD 4.88 intraday on October 20, 2026, compared with a 52-week range of USD 2.10 to USD 8.30. The current price was therefore 41.69 percent below the 52-week high. Market capitalization stood at USD 544.4 million, while the price-to-earnings ratio was negative 1.08.

For comparison, Huron Consulting Group traded at USD 181.90 on October 20, 2026, up 4.11 percent, with a price-to-earnings ratio of 27.41 and market capitalization of USD 2.9 billion. Omnicell traded at USD 36.60, up 2.22 percent, with a price-to-earnings ratio of 43.32 and market capitalization of USD 1.7 billion.

What analysts and dates indicate

MarketBeat reported on October 7, 2026 that 16 analysts had a Moderate Buy consensus, with an average 12-month target of USD 5.96. That target was 23.14 percent above the NYSE price of USD 4.84. The same report listed 11 Buy ratings, four Hold ratings and one Sell rating.

Yahoo Finance reported on October 9, 2026 that Evolent will release third-quarter 2026 financial results on November 5, 2026, before the NYSE opens, followed by a conference call at 8:30 a.m. ET. The scheduled report will test whether the rapid revenue growth can continue while operating results remain negative.

EUR 4.31 after hours

The euro quotation was EUR 4.31 at Lang & Schwarz on October 20, 2026 at 7:01 p.m. CEST. On the NYSE, Evolent stood at USD 4.84 at 1:05 p.m. ET on the same date, with the session showing an 8.04 percent gain from USD 4.48.

The further course of trading is shown by the continuously updated real-time quote of Evolent Health stock.